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A B S T R A C T   
Background: In March 2020, the United Kingdom Multiple Sclerosis Register (UKMSR) established an electronic case return form, designed collaboratively by MS 
neurologists, to record data about COVID-19 infections in people with MS (pwMS). 
Objectives: Examine how hospital admission and mortality are affected by disability, age and disease modifying treatments (DMTs) in people with Multiple Sclerosis 
with COVID-19. 
Methods: Anonymised data were submitted by clinical teams. Regression models were tested for predictors of hospitalisation and mortality outcomes. Separate 
analyzes compared the first and second ‘waves’ of the pandemic. 
Results: Univariable analysis found hospitalisation and mortality were associated with increasing age, male gender, comorbidities, severe disability, and progressive 
MS; severe disability showed the highest magnitude of association. Being on a DMT was associated with a small, lower risk. Multivariable analysis found only age and 
male gender were significant. Post hoc analysis demonstrated that factors were significant for hospitalisation but not mortality. In the second wave, hospitalisation 
and mortality were lower. Separate models of the first and second wave using age and gender found they had a more important role in the second wave. 
Conclusions: Features associated with poor outcome in COVID-19 are similar to other populations and being on a DMT was not found to be associated with adverse 
outcomes, consistent with smaller studies. Once in hospital, no factors were predictive of mortality. Reassuringly, mortality appears lower in the second wave.   
1. Background 
Following the global pandemic of the novel SARS-CoV2 (WHO. 
Statement on the Second Meeting of the International Health Regula-
tions 2005) infection (COVID-19), the UK population was required to 
‘lock-down’, in the first instance from the 23rd March 2020 and eased on 
14th August 2020 and again from the 5th November 2020 until the 2nd 
December 2020 in England (IfG, 2021a). People with MS (pwMS), some 
of whom experience chronic disability and/or receive 
immune-suppressing disease modifying drugs, have ongoing concerns 
and uncertainty around their risk of COVID-19. Given these un-
certainties, there is an ongoing need to explore the impact of COVID-19 
on people with MS. The UK Multiple Sclerosis Register (UKMSR) has 
been capturing longitudinal clinical and patient reported outcomes in 
* Corresponding author. 
E-mail address: r.m.middleton@swansea.ac.uk (R. Middleton).  
Contents lists available at ScienceDirect 
Multiple Sclerosis and Related Disorders 
journal homepage: www.elsevier.com/locate/msard 
https://doi.org/10.1016/j.msard.2021.103317 
Received 31 August 2021; Received in revised form 4 October 2021; Accepted 6 October 2021   
Multiple Sclerosis and Related Disorders 56 (2021) 103317
2
since 2011 (Middleton et al., 2018). In March 2020, a platform was 
established to allow clinicians to record data about pwMS, both 
admitted to hospital and treated at home, due to COVID-19. The UKMSR 
provided an electronic case return form (eCRF), designed collabora-
tively by the UK MS research community and with reference to a similar 
initiative in Italy (Sormani, 2020), capturing data about the COVID-19 
features, and the MS history. This form was made available, securely 
over the internet, to all MS neurologists in the UK. Given the rapid 
evolution of the symptomatology of the virus, it was important to cap-
ture a broad spectrum of measures, both about the COVID-19 infection 
and essential data specific to MS. There are a number of published 
clinical studies from the United States (Salter et al., 2021), Iran (Sah-
raian et al., 2020), Italy (Sormani, 2020), the Netherlands (Loonstra 
et al., 2020) and Scotland (Fernandes et al., 2020), but given differences 
in the impact of COVID-19, and the management of MS, throughout the 
world, it is helpful to understand how the infection impacts pwMS in 
different countries where different health systems operate and more 
specifically within the UK and how this has evolved over the pandemic. 
2. Objectives 
To report on hospitalisation and death in people with MS infected 
with COVID-19 in the UK, as recorded by MS specialist neurology cen-
tres through two peaks of disease in March 2020 and February 2021. 
3. Methods 
The UK MS Register has ethical approval from South-West Central 
Bristol Research Ethics Committee (16/SW/0194). All study data was 
anonymous. An eCRF was distributed to UK neurologists via email, so-
cial networks, and the UK Multiple Sclerosis Society. 
The requirement for data entry was a confirmed diagnosis of MS by a 
UK Neurologist and that the patient must be resident in the UK. For the 
purposes of analysis, we excluded those without a confirmed COVID-19 
infection, or with missing values for hospital admission status and 
outcome. The eCRF provided three options for confirmation of COVID- 
19 infection: a positive PCR test, positive SARS-CoV2 antibody test, or 
clinical confirmation based on presenting symptoms and other in-
vestigations e.g. typical chest imaging findings (Islam et al., 2021). 
The eCRF was created using REDCap (Harris et al., 2009) and data 
were analyzed using the R language (R Core Team, 2018). Validation 
was integrated into the eCRF (Appendix 1), with few response options 
being made mandatory, to allow for the difficulties of clinical data 
capture during the ongoing pandemic and not limit data capture. For the 
purposes of pre-analysis, some sub-categories of data were aggregated, 
in accordance with clinical advice. MS types were combined into either 
‘progressive’ (primary progressive MS and secondary progressive MS) or 
‘not progressive’ (relapsing remitting MS). The Expanded Disability 
Status Scale (EDSS) scores were categorised as ‘Mild’ (EDSS 0–2.5), 
‘Moderate’ (EDSS 3–5.5), and ‘Severe’ (EDSS ≥ 6). Details on the 
following comorbidities were collected: cardiovascular disease, dia-
betes, asthma, chronic obstructive pulmonary disease, other chronic 
lung disease, hypertension, cancer, stroke, chronic renal diseases, and 
chronic liver diseases. For analysis, these were aggregated into three 
categories of ‘Cardiovascular’ (cardiovascular diseases, hypertension 
and stroke), ‘Respiratory’ (asthma, chronic obstructive pulmonary dis-
ease and other chronic lung disease), and ‘Other’ (diabetes, cancer, 
chronic renal disease or chronic liver disease). Comorbidities were 
further aggregated into one yes/no measure of having ‘Any Comorbid-
ity’ for some analyzes. A complete data dictionary is available on 
request. 
Hospital admission (yes/no) and final recorded outcome (deceased/ 
alive) were combined into a status variable of “not admitted to hospital, 
now alive/recovering” to “admitted to hospital, now alive/recovering” 
to “admitted to hospital, now deceased” to summarise serious events. 
This was treated as a sliding scale of serious events (1 - “not hospitalised, 
alive” - 2 (“hospitalised, alive”) - 3 (“hospitalised, deceased”) to perform 
univariable and multivariable ordinal logistic regression for de-
mographic and clinical factors. The assumption of proportionality of 
odds was confirmed and Variance Inflation Factor (VIF) was calculated 
by converting the logistic model to a linear one, and t-tests, analysis of 
variance (ANOVA) and Pearson’s correlation were used to further 
explore interactions between independent variables. Variables were 
excluded from the multivariable model in a step-wise backwards 
fashion. 
Treating the three levels (“not hospitalised, alive”, “hospitalised, 
alive”, “hospitalised, deceased”) as nominal categories instead, further 
standardised hypothesis testing was conducted with the null hypothesis 
being that there was no association between the variable and the three 
potential outcomes. Chi-Squared and ANOVA were used in the first 
instance, with Fisher’s Exact substituted for Chi-Squared where ex-
pected values were small, and Kruskal-Wallis substituted for ANOVA 
where results were non-normal. Post-hoc pairwise comparisons using 
Bonferroni adjustment were calculated for factors achieving statistical 
significance (Table 2). 
The demographic and clinical factors chosen for inclusion were sex, 
age, MS type, EDSS, DMT treatment, comorbidities, and lymphocyte 
count prior to COVID-19 infection. With regards to DMT treatment, 
serious events were primarily assessed in terms of whether or not a 
patient was receiving a DMT at the time of infection. 
Some event-specific variables were examined separately for serious 
events of hospitalisation and death. For hospital admission, these 
included reasons for admission to hospital, duration of hospital stay, and 
signs and symptoms of infection. For mortality, signs and symptoms of 
infection, as well as severity, and respiratory support, were assessed. 
Certain features of the approach to COVID-19 diagnosis and treat-
ment changed over the course of the pandemic (of particular relevance 
here, given our inclusion/exclusion criteria, is that PCR tests became 
more readily available over time). To better understand the effects of 
these changes on our data, standard hypothesis tests (with a null hy-
pothesis assuming no association) were used to compare population 
demographics and clinical features from the ‘first wave’ (defined here as 
3rd March 2020 – 20th August 2020) and ‘second wave’ (21st August 
2020–16th March 2021 – as the end of this study). An ordinal logistic 
regression, using the independent variables chosen previously, was 
modeled on the first wave data and used to predict outcomes in the 
second wave data, and vice versa. The models were then used to 
compare the predictions of each model to both sets of data. 
4. Results 
4.1. Demographics 
Data on 292 individual pwMS (England: 232, Wales: 41, Northern 
Ireland: 15, unspecified location: 4) were entered by clinicians between 
27th March 2020 and 16th March 2021. Median age was 50 with an 
interquartile range (IQR: 42, 60), 68.5% were female. One hundred and 
seventy-three (59.3%) had relapsing-remitting MS, 103 (35.3%) had 
progressive (primary or secondary) and 16 (5.5%) had unknown MS 
type. Two hundred and twenty-four had last known EDSS scores prior to 
COVID-19 infection; 78 (34.8%) were ‘Mildly’, 51 (22.8%) ‘Moderately’, 
and 95 (42.4%) ‘Severely’ disabled. 
One hundred and sixty-eight (57.5%) pwMS had a positive poly-
merase chain reaction (PCR) test, 5 (1.7%) had a positive antibody test 
and 23 (7.9%) were clinically confirmed based on presenting symptoms 
and other investigations. Ninety-six (32.9%) pwMS were excluded 
because they did not have confirmed COVID-19 according to the 
methods specified. A further 3 patients were excluded because they had 
missing values for either hospital admission status or outcome. De-
mographics and clinical features for the 193 included pwMS are pro-
vided in Table 1. 
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4.2. Clinical features of hospitalised COVID-19 people with MS 
In the case of 85 pwMS who were hospitalised, 54 (63.5%) were due 
to COVID-19, 7 (8.2%) for reasons associated with MS, 4 (4.7%) for 
social reasons (where the patient was unable to be supported at home) 
and 20 (23.5%) for ‘other’ or ‘unknown’ reasons. A median 9 days in 
hospital was recorded and this duration of stay was the same for all 
admissions regardless of survival. Levels of respiratory support for those 
in hospital were divided into low-dependency (‘face mask’ or ‘nasal 
cannulae’) and high-dependency (‘high flow oxygen’, ‘non-invasive 
ventilation’ or ‘intubated and ventilated’), with a significant difference 
in survival rates between the two different intensity treatment levels 
(Fisher’s Exact test; CI 0.03, 0.48, p = 0.001). Symptoms of infection 
associated with admission included respiratory problems (χ2 13.17, df =
1, p < 0.001) and high temperature (χ2 13.98, df = 1, p < 0.001). 
Increasing age (t − 8.88, df 159.71), male gender (χ2 10.95, df = 1), 
having any comorbidity (χ2 39.83, df = 1), increased disability (χ2 
54.17, df = 2) and progressive MS (χ2 57.73, df = 1) were associated 
with being hospitalised (p < 0.001), while being on a DMT was associ-
ated with a lower likelihood of being admitted to hospital (χ2 35.05, df 
= 1, p < 0.001). 
4.3. Clinical features of people with ms dying as a result of COVID-19 
One person with MS with COVID-19 died at home. Of those hospi-
talised, 15 out of 85 (17.7%) died; 11 of those (73.3%) had either 
‘critical’ or ‘severe’ COVID-19 symptoms recorded compared to those 
who were admitted to hospital but survived (20%, p < 0.01)). 11 out of 
15 (73.3%) of those who died in hospital had required some form of 
ventilatory support, compared to 31 out of 70 (44.3%) who were 
admitted but recovered. In the group that died, respiratory symptoms 
were found to be amongst the most significant (χ2 3.74, df = 1, p = 0.05). 
4.4. Outcome analysis: hospitalisation and death 
Univariable ordinal logistic regression of serious events showed that 
male gender, older age, progressive disease, not being on active DMT 
treatment, and the presence of comorbidities were all significant 
(Table 1, p < 0.01), with age the most significant. In terms of disability, 
only severe disability was found to be significant. Lymphocyte count 
values prior to COVID-19 infection were not found to be significant. 
When multivariable modeling was used there was high (>2.5) VIF 
for progressive MS type and EDSS. Standardised hypothesis tests found 
that these, as well as DMT treatments, the ‘cardiac’ and ‘other’ and ‘any’ 
comorbidity categories were all significantly associated with age at a 
level of p < 0.01; younger pwMS were more likely to be on a DMT, more 
likely to not have progressive disease, and to not have comorbidities. 
Respiratory comorbidities were associated with higher age at a level of p 
= 0.02 (t − 2.48, df = 29.46). Removing these due to the high levels of 
interaction, as well as lymphocyte counts, left only age and gender in the 
multivariable model, both showing significance at p < 0.01, Residual 
Deviance 261.71, AIC 269.71. 
Treating the combined serious events as nominal categories, stand-
ardised hypothesis testing found significance in all factors at p < 0.01 
except for lymphocyte counts prior to infection (Table 2, column 1). 
Post-hoc pairwise comparisons (Table 2, columns 2–4) found that sig-
nificant differences were primarily found between the groups of those 
Alive, Hospitalised/Alive, Not Hospitalised, and Alive, Not Hospital-
ised/Deceased, Hospitalised, with no significant differences between the 
Alive, Hospitalised/Deceased, Hospitalised groups. 
4.5. Differences between first and second wave 
For this analysis, a further 21 pwMS from the confirmed COVID-19 
group were excluded due to missing values for estimated infection 
date. The likelihood of being hospitalised due to COVID-19 decreased in 
the second wave (χ2 = 35.40, df = 1, p < 0.001), as did the likelihood of 
death (Fisher test; CI 0.02, 0.91, p = 0.02). As presented in Table 3, in 
the second wave pwMS were more likely to be younger (t − 2.85, df 153), 
not have progressive MS (χ2 = 8.50, df = 1), have lower disability (χ2 =
8.67, df = 2) and more likely to be on a DMT (χ2 = 5.03, df = 1). 
An ordinal logistic regression, again using age and gender as inde-
pendent variables, was modeled on the first wave data, with age (OR 
1.08, CI [1.04, 1.12]) and gender (OR 0.19, CI [0.06, 0.55]) both found 
to be significant at p < 0.01, Residual Deviance 109.18, AIC 117.18. This 
was able to predict outcomes in the first wave with an accuracy of 
70.273% (CI 58.52%, 80.34%). Inaccurate predictions were a mixture of 
13 better and 9 worse outcomes. Applying this model to the second wave 
found it to be 57.14% accurate (CI 46.75%, 67.10%), and 39/42 of the 
inaccurate predictions were for worse outcomes. Thus the model that fits 
the first wave predicted many more worse outcomes than occurred in 
the second wave. Repeating the process in reverse, using the second 
wave data for the model showed age (OR 1.11, CI [1.06, 1.17], p < 0.01) 
and gender (OR 0.29, CI [0.09, 0.94], p = 0.04) were again significant 
with an accuracy of 83.67% (CI 74.84%, 90.37%), Residual Deviance 
86.46, AIC 94.46. 13/16 of the incorrect predictions were for better 
outcomes than happened. Applying this model to the first wave data 
gave an accuracy of 55.41 (CI 43.49%, 66.98%) and all predicted 
Table 1 
Clinical features of people with MS with confirmed COVID-19, with known 
hospital admission and outcome status. One person with MS who died at home 
was included in the ‘Deceased, Hospitalised’ category.   
Confirmed 
by Test (n =
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outcomes were better than the observed outcomes: 25 predictions were 
for the person would be alive without needing hospitalisation when in 
reality they were hospitalised, 4 predictions were for the person being 
alive but hospitalised when in reality they died, and 4 predictions were 
for the person being alive and not hospitalised when in reality they died. 
5. Discussion 
We present an overview of COVID-19 in pwMS from England, Wales 
and Northern Ireland, showing that the features associated with poor 
outcome in confirmed COVID-19 infection are similar to other non-MS 
populations reported around the world. We found a range of MS and 
non-MS factors appeared to be relevant to COVID-19 outcome, but in 
multivariable analysis only older age and male gender remained as 
significant predictors of poor outcome. We also demonstrated that these 
factors were associated with hospitalisation, but once hospitalised, none 
were associated with mortality. This implies that once in hospital fac-
tors, not quantified here, are predictive of mortality. 
Our findings are consistent with our community-based self-reported 
study in the UK where there were fewer pwMS self-reporting as being 
hospitalised (Evangelou et al., 2020), and with other Register-based 
studies (Louapre et al., 2020), which also found that pwMS on a DMT 
were not at an increased risk of a poor outcome, but contrasts with in-
ternational data on increased risks with some DMTs (Simpson-Yap et al., 
2021). However, in common with our findings they did not find that 
DMTs were associated with a higher mortality (Simpson-Yap et al., 
2021). This is perhaps because those on DMTs are generally younger and 
have lower levels of disability than those not on DMTs, would be less at 
risk of serious COVID outcomes and were also advised to self-isolate (IfG 
2021b). Thus, it seems likely in the UK that the behavior of people on 
DMTs is potentially an important factor. 
Reassuringly, we see that the outlook for COVID-19 in pwMS has 
improved in the second wave, as we observed younger, less progressive 
people having improved survival rates, in keeping with UK and other 
international results (IfG, 2021b; Griffin, 2020; James et al., 2021). Age 
and gender provided a better fit for the second wave model than the first, 
suggesting that the higher hospitalisation and mortality in the first wave 
may be attributed to other factors not accounted for in this data. 
Certainly, during the first wave there remains a concern about how 
decisions regarding treatment were made for those at-risk populations e. 
g. those above a certain age but also those with prior disabilities. These 
decisions were managed more cohesively following guidance for the 
second wave (Williamson et al., 2021; IfG, 2021). 
Limitations of our study largely relate to the fact that the data cap-
ture tool was devised at the outset of the pandemic; the understanding of 
the COVID-19 infection has evolved over the course of the pandemic. As 
a result, we did not capture ethnicity (Garjani et al., 2021) or body mass 
index (Razieh et al., 2020), which have subsequently been shown to be 
factors associated with increased mortality. 
Another factor was the limited availability of PCR testing in the first 
few weeks of the pandemic; this was eventually resolved through wider 
more effective testing, but it may have affected our analysis as several 
pwMS were excluded due to inconclusive COVID-19 status. 
As with all studies we have to be mindful of reporting bias 
(McGauran et al., 2010), particularly in a study such as this where data is 
‘volunteered’ by interested clinicians. Despite this, 46 different sites 
across England, Northern Ireland and Wales contributed data to this 
study across all time points. Reporting bias may also mean the most 
serious cases were reported, and milder community cases more likely to 
be missed. Additionally, pwMS on DMTs were potentially over-reported 
due to having a higher likelihood of being reviewed by neurologists due 
to their treatment regimen but ultimately the sample size as with other 
studies may have limited our ability to draw conclusions on DMTS. 
Table 2 
Standard hypothesis testing for nominal serious event categories, with post-hoc pairwise results for significant variables. Tests were conducted using Chi Squared and 
analysis of variance (ANOVA). Kruskal-Wallis test was substituted for ANOVA where results were non-normal, and Fisher’s Exact test was substituted for Chi Squared 
where expected values were small. Post-hoc pairwise comparisons using Bonferroni adjustment were calculated for factors achieving statistical significance.   
n Standard 
hypothesis test: p- 
value 
Post-hoc pairwise association tests, 
using Bonferroni adjustment: p- 
value   




Alive, Not Hospitalised/ 
Deceased, Hospitalised 
Gender: Female/Male, missing 134/59, 0 0.001 0.002 1.000 0.153 
Age (Years) Mean, Standard Deviation, missing 50.75, 
14.90, 0 
<0.001 <0.001 0.200 <0.001 
MS Type: progressive/not progressive, missing 74/112, 7 <0.001 <0.001 0.293 <0.001 
EDSS Group: mild/moderate/severe, missing 60/38/ 
74, 21 
<0.001 <0.001 0.708 <0.001 


























Lymphocyte Count Prior to Covid-19 Infection 




0.134 – – –  
Table 3 
Population demographics and clinical features of the first (n = 74) and second 
waves (n = 98). Tests were conducted using Chi Squared and analysis of variance 
(ANOVA). Kruskal-Wallis test was substituted for ANOVA where results were 
non-normal, and Fisher’s Exact test was substituted for Chi Squared where ex-
pected values were small.  
Characteristic First wave 
n = 74 
Second Wave 





48/26, 0 72/26, 0 0.294 




46 (37, 54), 0 0.005 
MS Type: progressive/not 
progressive, missing 
36/33, 5 28/70, 0 0.003 





38/24/29, 7 0.013 
DMT: yes/no, missing 35/35, 4 67/31, 0 0.025 
Hospitalised: yes/no, 
missing 
51/23, 0 22/76, 0 <0.001 
Deceased: yes/no, missing 8/66, 0 2/96, 0 0.020  
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6. Conclusion 
Increasing age was the most significant factor for risk of hospital-
isation and mortality in pwMS infected with COVID-19. Male gender, 
increasing disability, progressive MS, and the presence of comorbidities 
were also found to be associated with a higher risk whereas being on a 
disease modifying therapy was associated with a lower risk of hospi-
talisation and mortality. Once in hospital none of these factors were 
predictive of mortality. 
Fig. A1. Appendix 1: Example electronic case return form section.  
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